Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
Every day at Arvinas, we advance pioneering science to develop new, transformative treatments for patients with limited treatment options, or for whom existing treatments have not been effective.
Our values drive the work we do and the way we collaborate.
Unfortunately, it is hard to find anyone whose life is not touched by cancer or neurodegenerative disease. Our engagement with the patient community keeps us focused on our mission.
Join the Conversation
We’re very social. Chat with us on Twitter or LinkedIn!
We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. Check out our open positions, we’d love to hear from you.
PROTAC technology was invented at Yale University in New Haven, CT by the leading pioneer in the field, and we've been here ever since. We are proud of our New Haven roots and are committed to its emerging biotech community.
We see expansive potential for our PROTAC platform and we work with partners to extend its utility and reach, both in human therapeutics and crop protection.